Journal
EXPERIMENTAL DERMATOLOGY
Volume 26, Issue 8, Pages 728-730Publisher
WILEY
DOI: 10.1111/exd.13253
Keywords
chilblain lupus erythematosus; CXCL10; interferon; JAK/STAT pathway; kinase inhibitor
Categories
Funding
- Deutsche Forschungsgemeinschaft DFG [WE4428/1-2]
Ask authors/readers for more resources
This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2-kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho-JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available